Intravenous immunoglobulin (IVIG) efficiency in women with common variable immunodeficiency (CVID) decreases significantly during pregnancy
- PMID: 29614902
- DOI: 10.1080/14767058.2018.1455824
Intravenous immunoglobulin (IVIG) efficiency in women with common variable immunodeficiency (CVID) decreases significantly during pregnancy
Abstract
Immunoglobulin replacement therapy, including intravenous immunoglobulin (IVIG), is essential for pregnant women with common variable immunodeficiency (CVID) since it prevents infection and improves the health of the newborn. There are no established IVIG treatment protocols for pregnant women with CVID, and the relationship between IVIG treatment and maternal serum IgG changes during pregnancy remains unclear. Therefore, we reviewed the medical charts of four CVID patients, including one receiving subcutaneous immunoglobulin (SCIG), for IVIG dose and frequency, maternal serum IgG changes, obstetrical findings, and perinatal outcomes. There were no serious infections but one abortion and all patients continued therapy without IVIG-related adverse events. All eight children born to the patients were healthy at one month. However, the IVIG efficiency in those with CVID significantly decreased with progression of the gestational period, suggesting that IVIG dose and frequency may be changed during pregnancy to maintain stable serum IgG trough levels in women with CVID.
Keywords: Common variable immunodeficiency; immunoglobulin replacement therapy; pregnancy.
Similar articles
-
[Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].An Pediatr (Barc). 2009 Feb;70(2):111-9. doi: 10.1016/j.anpedi.2008.11.011. Epub 2009 Feb 3. An Pediatr (Barc). 2009. PMID: 19217565 Spanish.
-
The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID).Front Immunol. 2019 Jul 17;10:1541. doi: 10.3389/fimmu.2019.01541. eCollection 2019. Front Immunol. 2019. PMID: 31379811 Free PMC article.
-
Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency.J Investig Allergol Clin Immunol. 2011;21(7):514-21. J Investig Allergol Clin Immunol. 2011. PMID: 22312934
-
New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.Clin Exp Immunol. 2013 Nov;174(2):203-11. doi: 10.1111/cei.12178. Clin Exp Immunol. 2013. PMID: 23859429 Free PMC article. Review.
-
Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.J Clin Immunol. 2018 Nov;38(8):864-875. doi: 10.1007/s10875-018-0560-5. Epub 2018 Nov 10. J Clin Immunol. 2018. PMID: 30415311 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical